urinary peptides Classic Review,single peptide urinary biomarkers in CKD

Urinary peptides represent a fascinating and increasingly important area of medical research, offering a non-invasive glimpse into the complex physiological and pathological processes occurring within the human body. These small protein fragments, predominantly derived from the kidney and urinary tract, serve as valuable biomarkers for a wide range of conditions, from early renal damage to systemic diseases. The analysis of the urinary peptidome is revolutionizing diagnostics and prognosis, providing actionable insights for personalized medicine.

The scientific understanding of urinary peptides dates back decades, with early work in the 1950s and 1960s establishing peptiduria as a physiological phenomenon. However, advancements in analytical techniques, particularly mass spectrometry and bioinformatics, have propelled the field forward. Researchers can now establish highly reproducible, high-resolution methods for analyzing naturally occurring human urinary peptides and proteins. This allows for the detailed characterization of the human urine peptide atlas, a compendium of results from mass spectrometry proteomics datasets.

A key aspect of urinary peptides is their origin and composition. While some may be misnomers, the majority are indeed peptides. They are primarily formed through proteolytic activity, meaning they are products of the breakdown of larger proteins by enzymes called proteases. Extracellular proteases found in urine can reflect the presence of disease. Furthermore, urinary peptides are distinct from circulating proteins as they are filtered from the circulation by the kidney and excreted under physiological conditions. Importantly, urinary peptides are subjected to the activity of kidney-specific proteases, which are not present in circulation, adding another layer of complexity and specificity to their composition. Urinary proteins and peptides originate from the secretions of renal tubular epithelial cells, shedding of cells along the urinary tract, exosome secretion, and other cellular processes.

The diagnostic and prognostic power of urinary peptides lies in their ability to change in response to various health states. For instance, a specific set of urinary peptides has emerged as a predictor of new-onset proteinuria in patients with hypertension (HTN), enabling the early diagnosis of renal damage. Similarly, urinary peptidome analysis allows for the detection of short and long-term physiological or pathological changes occurring within the kidney. Research has shown that urinary peptides specifically depict inflammation and fibrosis, serving as a non-invasive tool to assess these conditions. Studies have identified seven fibrosis-associated peptides that display a significant negative correlation with the degree of fibrosis, highlighting their potential in understanding kidney disease progression. The value of urine peptides in assessing kidney and other organ functions is becoming increasingly evident.

Beyond kidney health, urinary peptides are proving to be valuable biomarkers for a broader spectrum of diseases. A urinary peptide classifier (COV50) has demonstrated its ability to predict disease progression and mortality from SARS-CoV-2 infection at an early stage. In the realm of oncology, five urinary peptides derived from uromodulin have been found to be significantly altered in prostate cancer (PCa), with reduced abundance in patients with the disease. Urinary peptides in heart failure are also under investigation, suggesting a link to molecular pathophysiology.

The application of urinary peptides extends to other critical areas of medicine. Research is exploring their role in trauma assessment, where urinary peptides provide information on patient outcomes and may guide personalized interventions. Even dietary factors can influence the urinary peptidome, as evidenced by studies identifying urinary gluten peptides following a gluten challenge.

The study of urinary peptidomics involves sophisticated analytical workflows. For example, LC-MS/MS and random forest (RF) algorithm can be employed to establish peptidomic profiles that distinguish different urinary peptidomic scenarios. Emerging technologies and computational approaches, such as machine learning-based urine peptidome analysis, are further enhancing our ability to uncover new pathophysiological pathways and predict risks. The Human Urine PeptideAtlas serves as a crucial resource, providing a compendium of data for researchers.

It is important to note that the integrity of urinary peptides can be affected by pre-analytical factors. For instance, a single freeze-thaw cycle can produce dramatic changes in the intensity of several urinary peptides, underscoring the need for careful sample handling.

The potential of urinary peptides is vast. They are being investigated for their role in conditions like inflammatory bowel disease (IBD) and idiopathic membranous nephropathy (IMN), where peptide fingerprints can reveal differences in naturally produced urinary peptide components. Furthermore, the discovery of antimicrobial peptides in the context of urinary tract infections suggests their therapeutic potential. Ultimately, the comprehensive analysis of urinary peptidome data from healthy individuals and patient cohorts provides a foundational understanding for identifying disease-specific signatures. The ongoing research into urinary peptides promises to unlock new diagnostic and therapeutic strategies, offering a less invasive and more informative approach to understanding human health.